HomeSingapore65LAB Launches in Partnership with Evotec

65LAB Launches in Partnership with Evotec


Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund, along with global life science company Evotec SE, announced the launch of 65LAB, a vehicle that advances drug discovery and new therapeutics companies in Singapore.

The first collaboration of its kind in Singapore, 65LAB will leverage the global capabilities of its partners – including financing, networks, company creation, and drug development expertise – to identify and accelerate the commercialization of the most promising research from top academic and R&D institutions in Singapore, the Agency for Science, Technology and Research (A*STAR), the National University of Singapore (NUS) and Duke-NUS Medical School (a collaboration between Duke University and NUS).

The partnership leverages breakthrough science from researchers at the Agency for Science, Technology and Research (A*STAR), the National University of Singapore (NUS) and Duke-NUS Medical School, for global health impact.

65LAB selects promising academic projects and invests up to US$1.5 million in each project over the course of 18-24 months. The collaboration enables scientists in partner institutions to accelerate their therapeutic innovations through the support of Evotec’s Expert-in-Residence, as well as direct access to the life science company’s drug discovery, translational and development capabilities across disease areas and therapeutic modalities. Upon completion, projects will be evaluated by 65LAB’s board of global investors for further investment and the creation of new companies.

The Board of Directors includes a team of world-leading biotech investors with broad expertise in company building and advancing a broad range of therapeutic modalities into and through the clinic. The board provides oversight and governance to 65LAB’s strategy and operations and includes Dr. Wen Qi Ho, Therapeutics Lead, ClavystBio, Dr. Christina Isacson, Partner, Lightstone Ventures, Dr. Pei Sze Ng, Director, Leaps by Bayer, and Dr. Kim Png, Principal, Polaris Partners.ù